<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03756415</url>
  </required_header>
  <id_info>
    <org_study_id>Stefano Nava1</org_study_id>
    <nct_id>NCT03756415</nct_id>
  </id_info>
  <brief_title>CO2 Clearance During Noninvasive Ventilation (NIV)</brief_title>
  <official_title>Evaluation of a New System to Clear CO2 During Noninvasive Ventilation (NIV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized cross over study the investigators will evaluate the effects on gas&#xD;
      exchange and patients' tolerance of a new CO2 non rebreathing devices incorporated in the&#xD;
      mask vs the traditional mask COPD patients undergoing NIV for an episode of Acute Hypercapnia&#xD;
      Respiratory Failure, will be randomized after at least 12 hour of ventilation to 1 h.trial&#xD;
      with the usual full face mask or the same mask with the addition of a new CO2 clearance&#xD;
      device&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this randomized cross over study the investigators will evaluate the effects on gas&#xD;
      exchange and patients' tolerance of a new CO2 non rebreathing devices incorporated in the&#xD;
      mask vs the traditional mask COPD patients undergoing NIV for an episode of Acute Hypercapnia&#xD;
      Respiratory Failure, will be randomized after at least 12 hour of ventilation to 1 h.trial&#xD;
      with the usual full face mask (FM) or the same mask with the addition of a new CO2 clearance&#xD;
      device (FM+d) In the interval between NIV sessions, arterial blood gases will be monitored&#xD;
      and if PaCO2 will return to a baseline value with a tolerance of 10%, the patients will&#xD;
      undergo another 1 h trial using the other mask.&#xD;
&#xD;
      The subjects will be studied in the sitting position and asked to relax throughout the period&#xD;
      of the study.&#xD;
&#xD;
      The patients will be ventilated using pressure support ventilation (PSV) The order of use of&#xD;
      the two interfaces will be determined for each patient by a previously generated randomized&#xD;
      sequence.&#xD;
&#xD;
      FIO2 will be adjusted to obtain oxygen saturation around 92% at baseline and never modified&#xD;
      throughout the study.&#xD;
&#xD;
      End-expiratory pressure will always fixed at 2 cm H2O, and trigger sensitivity will set at&#xD;
      -0.5 cm H2O.&#xD;
&#xD;
      Inspiratory assistance during either PSV will be titrated to achieve a tidal volume between&#xD;
      6-8 mL/kg while avoiding occurrence of discomfort or visually assessed &quot;wasted efforts&quot;.&#xD;
&#xD;
      The ventilatory settings will determined at the beginning of the first trial, and maintained&#xD;
      unmodified throughout all the 3 runs.&#xD;
&#xD;
      Patient tolerance to NIMV, defined as the level of comfort using the different mask, will be&#xD;
      assessed by means of a scale used and validated in previous studies that is defined as&#xD;
      follows: 1, bad; 2, poor; 3, sufficient; 4, good; 5, very good. The patients were asked by&#xD;
      the respiratory therapist to answer the following question: &quot;How do the patient feel your&#xD;
      breathing is using this mask?&quot; The patient will give the score to the therapist at the end of&#xD;
      each run, just before ABG measurements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in arterial blood gases (ABGs)</measure>
    <time_frame>immediate</time_frame>
    <description>Recording of carbon dioxide arterial tensione and oxygen arterial tension using an arterial puncture performed in the radial artery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>patient's tolerance to the mask</measure>
    <time_frame>immediate</time_frame>
    <description>the tolerance will be recorded using an ad hoc scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Hypercapnic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>mask plus CO2 removal device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a &quot;traditional&quot; mask with inserted a new CO2 removal device that is called DiMax Zero Total face mask &quot;R&quot;,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>traditional face mask</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Traditional mask without a CO2 clearance device inserted</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DiMax Zero Total face mask &quot;R&quot;,</intervention_name>
    <description>a non-CO2 rebreathing device included directly in the full face mask</description>
    <arm_group_label>mask plus CO2 removal device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>traditional face mask</intervention_name>
    <description>a traditional mask without a non-CO2 rebreathing device included directly in the full face mask</description>
    <arm_group_label>traditional face mask</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COPD diagnosis&#xD;
&#xD;
          -  sign inform consent&#xD;
&#xD;
          -  able to tolerate the application of NIV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inability to tolerate the mask&#xD;
&#xD;
          -  contraindication to NIV&#xD;
&#xD;
          -  cancer, neurological diseases, and need of another life support besides the ventilator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>stefano nava</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Sant'Orsola</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>stefano nava</last_name>
    <phone>3333751828</phone>
    <email>stefanava@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>vittoria comellini</last_name>
    <email>vittoria.comellini@aosp.bo.it</email>
  </overall_contact_backup>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 23, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>November 26, 2018</last_update_submitted>
  <last_update_submitted_qc>November 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>dr. Stefano Nava</investigator_full_name>
    <investigator_title>Chief of Pulmonary and Critical Care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>not allow to release individual data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

